Pharvaris publishes review on bradykinin B2 receptor as therapy target
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
July 22, 2026 6:50 AM EDTProvides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases
ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs... More
